Fulgent Genetics, Inc.
FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancerā¦ read more
Healthcare
Diagnostics & Research
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$16.55
Price-18.11%
-$3.66
1Y
Price
Market Cap
$470.030m
Small
Price/Earnings 3y Avg5y Avg
1,655x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-0.1%
EBITDA Margin-7.9%
Net Profit Margin+6.0%
Free Cash Flow Margin-0.1%
EBITDA Margin-7.9%
Net Profit Margin+6.0%
Free Cash Flow MarginRevenue
$323.932m
+11.3%
1y CAGR-14.6%
3y CAGR-20.4%
5y CAGREarnings
-$84.382m
-0.6%
1y CAGR-47.7%
3y CAGR-53.7%
5y CAGREPS
-$2.82
+2.1%
1y CAGR-48.2%
3y CAGR-54.0%
5y CAGRBook Value
$995.986m
$1.089b
Assets$93.237m
Liabilities$482k
DebtDebt to Assets
0.0%
-0.2x
Debt to EBITDAFree Cash Flow
-$103.787m
-3.1%
1y CAGR-200.8%
3y CAGR-164.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company